För investerare
Allt om läkemedelskandidaten arfolitixorin
och relaterad information
Urval av publikationer
Nedan följer ett urval av tillgängliga publikationer med arfolitixorin.
”The importance of treatment handling and compliance on overall response rate in a phase III study of metastatic colorectal cancer: Post-hoc per protocol analyses of the AGENT trial”.
Aldina Pivodic et al.
”Dose-dependent cytotoxicity of arfolitixorin, a direct-acting folate, versus leucovorin with 5-fluorouracil in patient-derived colorectal cancer tumoroids (PDTs)”
Dr Jarle Bruun et al.
”Final Analysis of the Greek cohort of the AGENT Phase III study Arfolitixorin in Metastatic Colorectal Cancer”
Anna Koumarianou et al.
Nedan följer ett urval av tillgängliga publikationer med arfolitixorin.
”A Randomized Phase III Study of Arfolitixorin Versus Leucovorin with 5-Fluorouracil, Oxaliplatin and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial”
J. Tabernero et al.
Cancer Research Communications >>
”A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer”
G Carlsson et al.
ESMO Open, volume 7, issue 5, 100589, October 2022 >>
”Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone”
BengtGlimelius, et al
Cancer Treatment Review, Volume 98, July 2021 >>
”MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer”
David A. Drubin, et al.
”Tumoral expression of folate-associated genes is associated with progression-free survival of patients with advanced colorectal cancer”
Yvonne Wettergren, et al.
“Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy”
Roger Tell, et al.
”Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin”
Helena Taflin, et al.
Springer Link, Oktober, 2020 >>
”An open-label Phase III study of arfolitixorin vs leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer”
Heinz-Josef Lenz, et al.
”Open-label Phase III Study of Arfolitixorin vs Leucovorin in Modifi ed FOLFOX-6 for First-line Treatment of Metastatic Colorectal Cancer: AGENT”.
Stintzing, Sebastian, et al.
”ISO-CC-005; a phase I/II study of arfolitixorin ([6R]-5,10-MTHF) in combination with 5-fluorouracil (5-FU), irinotecan and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer”.
Carlsson, Göran, et al.
”Folate gene prediction of treatment response to 5-FU and leucovorin in metastasizing colorectal cancer”.
Gustavsson, Bengt, et al.
”A review of the evolution of systemic chemotherapy in the management of colorectal cancer”.
Gustavsson, Bengt, et al.
Clinical colorectal cancer 14.1 (2015): 1-10 >>
”Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action”.
Danenberg, Peter V., et al.
Critical Reviews in Oncology/Hematology 106 (2016): 118-131 >>
”Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages.”
Taflin, Helena, et al.
Cancer chemotherapy and pharmacology 74.6 (2014): 1167-1174 >>
Senast uppdaterad 2025-01-25
